Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Gemcitabine in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Lurbinectedin (Primary) ; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
- 12 Nov 2016 Results published in the Investigational New Drugs
- 05 Nov 2013 New trial record